Peptide Education Manager
Edit Semax
Name
Scientific / Common Name
Alternative Names
Slug (url-safe, unique)
Short Description (shown on cards)
A synthetic peptide originally developed in Russia and studied, mostly outside the US, for cognitive and neuroprotective research interest.
Overview — What Is It? (paragraphs)
Semax is a synthetic peptide fragment related to ACTH (adrenocorticotropic hormone) that was developed and primarily studied in Russia, where it has a longer history of clinical use for certain neurological conditions under that country's regulatory framework. It has not undergone the same clinical trial process required for FDA approval in the United States. Research interest in Semax centers on its proposed effects on brain-derived neurotrophic factor (BDNF) and related neurochemical pathways, which researchers have studied in the context of focus, memory, and neuroprotection. Much of the published literature on Semax originates from a specific research tradition and has had limited independent replication in Western, peer-reviewed clinical trials.
Why Being Studied (one item per line)
Brain-derived neurotrophic factor (BDNF) signaling Focus and attention research Memory and learning pathways Neuroprotection research models
How It May Work
Semax is proposed to influence levels of BDNF and related neurotrophic factors, which are involved in neuron growth, survival, and synaptic plasticity. Researchers have also studied its relationship to the dopaminergic and serotonergic systems in animal models.
Mechanism Pathway Steps (one per line)
Semax Proposed BDNF & neurotrophic factor signaling Neuronal plasticity & neurochemical pathways Cognitive outcomes studied primarily outside the US
Evidence Rating
Established / Approved Use
Strong Human Evidence
Moderate Human Evidence
Early Human Evidence
Preclinical Evidence
Emerging / Limited Evidence
Human Evidence
Human research on Semax has largely been conducted and published within Russia, with limited independent replication in Western peer-reviewed clinical trials. Rigorous, large-scale randomized controlled trial data is not widely available.
Preclinical Evidence
Animal studies have examined Semax's effects on BDNF expression and behavioral markers related to learning and memory.
What We Don't Know Yet
Whether findings from the existing research base, much of which has limited independent replication, translate reliably to broader populations and long-term use has not been established.
Research Area Cards (format: Title: description — one per line)
Cognitive Health: Semax's proposed effect on neurotrophic signaling is the central focus of research interest.
Why Might Someone Discuss This With Their Provider?
Someone interested in cognitive performance research or nootropic peptides may encounter Semax while exploring neurochemical pathway therapies.
Regulatory Status
Semax is not approved by the FDA for any use in the United States and is not an FDA-approved drug product.
Important Considerations
Much of the existing evidence base has limited independent replication outside of its country of origin. Discuss any interest in cognitive-focused peptides with a licensed healthcare provider.
Related Peptide Slugs (one per line)
selank
Is Combination Product?
Categories / Goals
Recovery & Repair
Metabolic Health
Weight Management
Performance
Muscle & Body Composition
Sleep & Recovery
Cognitive Health
Stress & Mood
Longevity & Healthy Aging
Cellular Energy
Skin, Hair & Aesthetics
Sexual Wellness
Search Tags (comma separated)
Last Reviewed Date
Display Order
Published
Featured
Save Peptide